BCL2 and B-cell chronic lymphocytic leukemia: Similarly, sonrotoclax, another second-generation BCL-2 inhibitor, has shown high efficacy against venetoclax-resistant BCL-2 mutations, including the G101V mutation frequently observed in CLL patients who relapse after venetoclax therapy.